• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form D filed by bioAffinity Technologies Inc.

    10/29/24 1:54:51 PM ET
    $BIAF
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $BIAF alert in real time by email
    SEC FORM D

    The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
    The reader should not assume that the information is accurate and complete.

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM D

    Notice of Exempt Offering of Securities

    OMB APPROVAL
    OMB Number: 3235-0076
    Estimated average burden
    hours per response: 4.00

    1. Issuer's Identity

    CIK (Filer ID Number) Previous Names
    X None
    Entity Type
    0001712762
    X Corporation
       Limited Partnership
       Limited Liability Company
       General Partnership
       Business Trust
       Other (Specify)

    Name of Issuer
    bioAffinity Technologies, Inc.
    Jurisdiction of Incorporation/Organization
    DELAWARE
    Year of Incorporation/Organization
    X Over Five Years Ago
       Within Last Five Years (Specify Year)
       Yet to Be Formed

    2. Principal Place of Business and Contact Information

    Name of Issuer
    bioAffinity Technologies, Inc.
    Street Address 1 Street Address 2
    3300 NACOGDOCHES ROAD SUITE 216
    City State/Province/Country ZIP/PostalCode Phone Number of Issuer
    SAN ANONIO TEXAS 78217 (210) 698-5334

    3. Related Persons

    Last Name First Name Middle Name
    Zannes Maria
    Street Address 1 Street Address 2
    3300 Nacogdoches Road Suite 216
    City State/Province/Country ZIP/PostalCode
    San Anonio TEXAS 78217
    Relationship: X Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Edwards James
    Street Address 1 Street Address 2
    3300 Nacogdoches Road Suite 216
    City State/Province/Country ZIP/PostalCode
    San Antonio TEXAS 78217
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):

    In connection with the offering, the placement agent received a cash placement fee equal to 8.0% of the gross proceeds received from the sale of the securities sold in the registered direct offering and the private placement among other items.
    Last Name First Name Middle Name
    Zannes Timothy P.
    Street Address 1 Street Address 2
    3300 Nacogdoches Road Suite 216
    City State/Province/Country ZIP/PostalCode
    San Antonio TEXAS 78217
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Rebel Vivienne
    Street Address 1 Street Address 2
    3300 Nacogdoches Road Suite 216
    City State/Province/Country ZIP/PostalCode
    San Antonio TEXAS 78217
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Reveles Xavier
    Street Address 1 Street Address 2
    3300 Nacogdoches Road Suite 216
    City State/Province/Country ZIP/PostalCode
    San Antonio TEXAS 78217
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Joyce Roby
    Street Address 1 Street Address 2
    3300 Nacogdoches Road Suite 216
    City State/Province/Country ZIP/PostalCode
    San Antonio TEXAS 78217
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Diamond Stuart
    Street Address 1 Street Address 2
    3300 Nacogdoches Road Suite 216
    City State/Province/Country ZIP/PostalCode
    San Antonio TEXAS 78217
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Knight Peter S.
    Street Address 1 Street Address 2
    3300 Nacogdoches Road Suite 216
    City State/Province/Country ZIP/PostalCode
    San Antonio TEXAS 78217
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Rubin Gary
    Street Address 1 Street Address 2
    3300 Nacogdoches Road Suite 216
    City State/Province/Country ZIP/PostalCode
    San Antonio TEXAS 78217
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Girgenti Steven
    Street Address 1 Street Address 2
    3300 Nacogdoches Road Suite 216
    City State/Province/Country ZIP/PostalCode
    San Antonio TEXAS 78217
    Relationship: X Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Anderson Robert
    Street Address 1 Street Address 2
    3300 Nacogdoches Road Suite 216
    City State/Province/Country ZIP/PostalCode
    San Antonio TEXAS 78217
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Platt Jamie
    Street Address 1 Street Address 2
    3300 Nacogdoches Road Suite 216
    City State/Province/Country ZIP/PostalCode
    San Antonio TEXAS 78217
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    4. Industry Group

       Agriculture
    Banking & Financial Services
       Commercial Banking
       Insurance
       Investing
       Investment Banking
       Pooled Investment Fund
    Is the issuer registered as
    an investment company under
    the Investment Company
    Act of 1940?
       Yes    No
       Other Banking & Financial Services
       Business Services
    Energy
       Coal Mining
       Electric Utilities
       Energy Conservation
       Environmental Services
       Oil & Gas
       Other Energy
    Health Care
    X Biotechnology
       Health Insurance
       Hospitals & Physicians
       Pharmaceuticals
       Other Health Care
       Manufacturing
    Real Estate
       Commercial
       Construction
       REITS & Finance
       Residential
       Other Real Estate
      
    Retailing
      
    Restaurants
    Technology
       Computers
       Telecommunications
       Other Technology
    Travel
       Airlines & Airports
       Lodging & Conventions
       Tourism & Travel Services
       Other Travel
      
    Other

    5. Issuer Size

    Revenue Range OR Aggregate Net Asset Value Range
       No Revenues    No Aggregate Net Asset Value
       $1 - $1,000,000    $1 - $5,000,000
       $1,000,001 - $5,000,000    $5,000,001 - $25,000,000
       $5,000,001 - $25,000,000    $25,000,001 - $50,000,000
       $25,000,001 - $100,000,000    $50,000,001 - $100,000,000
       Over $100,000,000    Over $100,000,000
    X Decline to Disclose    Decline to Disclose
       Not Applicable    Not Applicable

    6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

       Rule 504(b)(1) (not (i), (ii) or (iii))
       Rule 504 (b)(1)(i)
       Rule 504 (b)(1)(ii)
       Rule 504 (b)(1)(iii)
    X Rule 506(b)
       Rule 506(c)
       Securities Act Section 4(a)(5)
       Investment Company Act Section 3(c)
       Section 3(c)(1)    Section 3(c)(9)  
       Section 3(c)(2)    Section 3(c)(10)
       Section 3(c)(3)    Section 3(c)(11)
       Section 3(c)(4)    Section 3(c)(12)
       Section 3(c)(5)    Section 3(c)(13)
       Section 3(c)(6)    Section 3(c)(14)
       Section 3(c)(7)

    7. Type of Filing

    X New Notice Date of First Sale 2024-10-21    First Sale Yet to Occur
       Amendment

    8. Duration of Offering

    Does the Issuer intend this offering to last more than one year?
       Yes X No

    9. Type(s) of Securities Offered (select all that apply)

    X Equity    Pooled Investment Fund Interests
       Debt    Tenant-in-Common Securities
    X Option, Warrant or Other Right to Acquire Another Security    Mineral Property Securities
    X Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security    Other (describe)

    10. Business Combination Transaction

    Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?
       Yes X No

    Clarification of Response (if Necessary):

    11. Minimum Investment

    Minimum investment accepted from any outside investor $0 USD

    12. Sales Compensation

    Recipient
    Recipient CRD Number    None
    Wallachbeth Capital LLC 000147853
    (Associated) Broker or Dealer X None
    (Associated) Broker or Dealer CRD Number X None
    None None
    Street Address 1 Street Address 2
    1001 Yamato Road Suite 404
    City State/Province/Country ZIP/Postal Code
    Boca Raton FLORIDA 33431
    State(s) of Solicitation (select all that apply)
    Check “All States” or check individual States
       All States
       Foreign/non-US
    NEW YORK

    13. Offering and Sales Amounts

    Total Offering Amount $3,994,173 USD
    or    Indefinite
    Total Amount Sold $0 USD
    Total Remaining to be Sold $3,994,173 USD
    or    Indefinite

    Clarification of Response (if Necessary):

    The total offering amount reflects the total gross proceeds to be received assuming cash exercise of all warrants issued in the private placement.

    14. Investors

      
    Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.
    Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
    5

    15. Sales Commissions & Finder's Fees Expenses

    Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

    Sales Commissions $213,023 USD
    X Estimate
    Finders' Fees $0 USD
       Estimate

    Clarification of Response (if Necessary):

    In connection with the offering, the placement agent received a cash placement fee equal to 8.0% of the gross proceeds received from the sale of the securities sold in the registered direct offering and the private placement among other items.

    16. Use of Proceeds

    Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

    $0 USD
       Estimate

    Clarification of Response (if Necessary):

    Signature and Submission

    Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

    Terms of Submission

    In submitting this notice, each issuer named above is:
    • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
    • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of:  (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
    • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

    Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

    For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

    Issuer Signature Name of Signer Title Date
    bioAffinity Technologies, Inc. /s/ Maria Zannes Maria Zannes President & CEO 2024-10-29

    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

    * This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.


    Get the next $BIAF alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BIAF

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BIAF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operating Officer Reveles Xavier Trinidad was granted 21,604 shares, increasing direct ownership by 106% to 41,943 units (SEC Form 4)

      4 - bioAffinity Technologies, Inc. (0001712762) (Issuer)

      1/14/25 4:15:26 PM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Secretary, EVP, Gen. Counsel Zannes Timothy P was granted 8,641 shares, increasing direct ownership by 19% to 54,765 units (SEC Form 4)

      4 - bioAffinity Technologies, Inc. (0001712762) (Issuer)

      1/14/25 4:15:20 PM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • President & CEO Zannes Maria was granted 37,037 shares, increasing direct ownership by 15% to 280,359 units (SEC Form 4)

      4 - bioAffinity Technologies, Inc. (0001712762) (Issuer)

      1/14/25 4:15:23 PM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $BIAF
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $BIAF
    SEC Filings

    See more
    • bioAffinity Technologies Scientists Present Breakthrough Cancer Research at RNA Therapeutics Conference

      bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on cancer diagnostics and targeted therapeutics, will present findings today related to the discovery of a potential broad-spectrum cancer therapy that is the subject of the Company's recently issued U.S. Patent No. 12,305,171 and the notification of patent grant from the China National Intellectual Property Administration. The presentation at the 2025 RNA Therapeutics Conference, titled "Silencing CD320 and LRP2 by siRNAs selectively kills cancer cells: mechanistic enigmas," highlights a novel therapeutic approach that uses small interfering RNAs (siRNAs) to selectively kill cancer cells by targeting tw

      6/26/25 9:00:00 AM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • bioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer Therapy

      Company research targets topical application for treatment of skin cancers bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company advancing early-stage diagnostics and targeted therapeutics for cancer, today announced that the China National Intellectual Property Administration (CNIPA) has issued a notification of patent grant for the company's novel composition and method for selectively killing cancer by targeting the CD320 and LRP2 receptors on the cell membrane. The newly allowed Chinese patent – titled "Compositions and Methods for Treating Cancer" – adds important global protection for bioAffinity's innovative RNA-based therapeutic strategy and covers siRNAs

      6/24/25 9:00:00 AM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • bioAffinity Technologies President and CEO Maria Zannes Appointed to American Lung Association in Texas' Leadership Board

      bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other diseases of the lung, today announced that its President and CEO, Maria Zannes, has been selected to serve on the American Lung Association in Texas' Leadership Board, a distinguished group of healthcare professionals and advocates committed to advancing lung health. As a member of the Texas Leadership Board, Ms. Zannes will play an important role in supporting the Lung Association's mission to improve lives by preventing lung disease and promoting lung health through research, education and advocacy. Board

      6/11/25 9:00:00 AM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form POS AM filed by bioAffinity Technologies Inc.

      POS AM - bioAffinity Technologies, Inc. (0001712762) (Filer)

      6/27/25 4:53:08 PM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form POS AM filed by bioAffinity Technologies Inc.

      POS AM - bioAffinity Technologies, Inc. (0001712762) (Filer)

      6/27/25 4:50:32 PM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form DEFA14A filed by bioAffinity Technologies Inc.

      DEFA14A - bioAffinity Technologies, Inc. (0001712762) (Filer)

      6/2/25 5:29:21 PM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $BIAF
    Leadership Updates

    Live Leadership Updates

    See more
    • bioAffinity Technologies President and CEO Maria Zannes Appointed to American Lung Association in Texas' Leadership Board

      bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other diseases of the lung, today announced that its President and CEO, Maria Zannes, has been selected to serve on the American Lung Association in Texas' Leadership Board, a distinguished group of healthcare professionals and advocates committed to advancing lung health. As a member of the Texas Leadership Board, Ms. Zannes will play an important role in supporting the Lung Association's mission to improve lives by preventing lung disease and promoting lung health through research, education and advocacy. Board

      6/11/25 9:00:00 AM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • bioAffinity Technologies Appoints Dr. Gordon Downie, MD, PhD, as Chief Medical Officer

      bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer, today announced the appointment of Gordon Downie, MD, PhD, as its new Chief Medical Officer (CMO). Dr. Downie brings more than three decades of experience in pulmonary medicine, clinical research, medical innovation, and interventional pulmonology to the role. Dr. Downie has authored more than 30 peer-reviewed publications, many centered on innovation in bronchoscopy, early lung cancer diagnosis and medical device development. He has worked extensively in both academic medicine and private practice, led FDA-approved resea

      5/20/25 9:00:00 AM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development

      Dr. William Bauta, bioAffinity Senior Vice President of Research and Development and former Associate Director of Science at Genzyme and Ilex, steps into new role with the retirement of Dr. Vivienne Rebel bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)) ("bioAffinity" or the "Company"), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage lung cancer and other lung diseases, today announced that William Bauta, Ph.D., has been appointed Chief Science Officer. Before joining bioAffinity in 2016 as Senior Vice President of Research and Development, Dr. Bauta was the Associate Director of Science at Genzyme Corporation and held a similar positi

      11/4/24 8:00:00 AM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $BIAF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by bioAffinity Technologies Inc.

      SC 13G - bioAffinity Technologies, Inc. (0001712762) (Subject)

      10/10/23 6:03:06 AM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $BIAF
    Financials

    Live finance-specific insights

    See more
    • Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / January 10, 2025 / RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (NASDAQ:ENLV) and bioAffinity Technologies, Inc. (NASDAQ:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, January 11, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:ENLV: https://www.redchip.com/assets/access/enlv_accessBIAF: https://www.redchip.com/assets/access/biaf_accessIn an exclusive interview, Oren Hershkovitz, CEO of Enlivex Therapeutics, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to provide a c

      1/10/25 9:00:00 AM ET
      $BIAF
      $ENLV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Biotricity and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / July 12, 2024 / RedChip Companies will air interviews with Biotricity, Inc. (NASDAQ:BTCY) and bioAffinity Technologies, Inc. (NASDAQ:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 13, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Biotricity: https://www.redchip.com/assets/access/btcy_accessbioAffinity Technologies: https://www.redchip.com/assets/access/biaf_accessIn an exclusive interview, Dr. Waqaas Al-Siddiq, Founder and CEO of Biotricity, will share insight into the company's innovative portfolio of car

      7/12/24 9:35:00 AM ET
      $BIAF
      $BTCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
      Medical/Dental Instruments
    • BioVie and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / July 5, 2024 / RedChip Companies will air interviews with BioVie, Inc. (NASDAQ:BIVI) and bioAffinity Technologies, Inc. (NASDAQ:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 6, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:BioVie: https://www.redchip.com/assets/access/bivi_accessbioAffinity Technologies: https://www.redchip.com/assets/access/biaf_accessIn an exclusive interview, Cuong Do, President and CEO of BioVie, who will share insight into the Company's pipeline of late-stage clinical programs target

      7/5/24 9:00:00 AM ET
      $BIAF
      $BIVI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
      Biotechnology: Pharmaceutical Preparations